Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.
EU 15: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Spain, Sweden and the United Kingdom
EU 12: Bulgaria, Czech Republic, Estonia, Cyprus, Latvia, Lithuania, Hungary, Malta, Poland, Romania, Slovenia, Slovakia
In some years data were combined because of missing information from 2 years' data but represent clients for only one year on average.
Estimates for 1993 and 1995 derived from: Farrell, M., Verster, A., Davoli, M., et al. (2000) Reviewing Current Practice in Drug-substitution Treatment in the European Union. EMCDDA Insights No 3, Lisbon, p 22. Farrell, M., Neeleman, J., Gossop, M., et al
Datasets for 1997/1998 and 2001/2002 were published in the 2003 EMCDDA Annual Report, Table 3 .
Data for 2003 and 2005 were provided by NFPs through Standard Table 21 'Treatment availability' submitted in 2004 and 2006. Value for 2003 is underestimate as data for Scotland and N. Ireland not available.
Data for 2007 see Statistical Bulletin 2009, Table HSR-3 part (i) .
Data for 2008 see Statistical Bulletin 2010, Table HSR-3 part (i) .
(see the help page for information about formats etc.)
Page last updated: Tuesday, 04 January 2011